The enzyme β-carotene oxygenase 1 (BCO1) catalyzes the breakdown of provitamin A, including beta-carotene (BC), into retinal, prior to its oxidation into retinoic acid (RA). Allelic variation at the BCO1 locus results in differential expression of its mRNA and affects carotenoid metabolism specifically in chicken Pectoralis major muscle. In this context, the aim of this study was to evaluate the potential myogenic effect of BC and the underlying mechanisms in chicken myoblasts. BCO1 mRNA was detected in myoblasts derived from chicken satellite cells. Treating these myoblasts with BC led to a significant decrease in BrdU incorporation. This antiproliferative effect was confirmed by a cell cycle study using flow cytometry. BC also significantly increased the differentiation index, suggesting a positive effect on the commitment of avian myoblasts to myogenic differentiation. Addition of DEAB, a specific inhibitor of RALDH activity, significantly reduced BC antiproliferative and pro-differentiating effects, suggesting that BC exerted its biological effect on chicken myoblasts through activation of the RA pathway. We also observed that in myoblast showing decreased BCO1 expression consecutive to a natural mutation or to a siRNA treatment, the response to BC was inhibited. Nevertheless, BCO1 siRNA transfection increased expression of BCO2 which inhibited cell proliferation in control and BC treated cells.
Beta-carotene preferentially regulates chicken myoblast proliferation withdrawal and differentiation commitment via BCO1 activity and retinoic acid production 
Introduction
Vitamin A is essential for the life of all chordates and has numerous important functions: role in vision [1] , epithelium maintenance [2, 3] , immune competence [4] , reproduction, embryonic growth and development [5] , and is neuroprotective [6] . Vitamin A exists in three active forms into the cell (retinol, retinal and retinoic acid) and is defined as any compound that has the biological activity of retinol. Vitamin A in the retinol form is present in food of animal origin like liver, meat, milk, eggs…, while some carotenoids present in vegetable food, are precursors (provitamins) of vitamin A in animals. The provitamin A carotenoids, β-carotene (BC), α-carotene and β-cryptoxanthin are converted with decreasing efficiency into retinal [7] . In vitro, BC inhibits DNA synthesis in human aortic smooth muscle cells [8] .
The cleavage of BC into retinal by the β-carotene oxygenase 1 (BCO1) enzyme was first described in rat liver and intestine [9, 10] . The BCO1 gene in chicken and mammals [11, 12] is expressed at high levels in duodenum and liver where the major part of BC conversion occurs [13] . However, in some species a significant amount of carotenoids is not cleaved in the intestine and enters the circulation [14] [15] [16] [17] . Carotenoids in serum are presumably delivered to target cells by the LDL receptor [18] . As skeletal muscle expresses BCO1 [19] , this tissue is a potential target of provitamin A. In chicken, our laboratory described a polymorphism in the putative promoter of the BCO1 gene. This polymorphism is associated with a differential expression of this gene [19] and a differential accumulation of carotenoids, specifically in the Pectoralis major muscle [20] . Otherwise, in zebrafish, BCO1 seems to play a key role in local retinoic acid synthesis during embryonic development [21] .
Provitamin A carotenoids cleavage produces retinal which is then converted into retinoic acid (RA) by retinaldehyde dehydrogenase (RALDH), a member of the aldehyde dehydrogenase (ALDH) enzyme family [22] . A recent study demonstrated that a skeletal muscle cell population selected for a high ALDH activity shows an enhanced myogenic capacity, particularly in cell transplantation assays [23] . Furthermore, a high ALDH-activity is correlated with a resistance to the cytotoxic effect induced by hydrogen peroxide on human myoblasts [24, 25] . This suggests that ALDH activity is involved in both cell differentiation (through the RA pathway) and survival (through detoxification of toxic aldehydes).
Through its effect on gene expression, RA has a key role in cell differentiation, especially in skeletal muscle. In fact, RA inhibits myoblast proliferation and induces muscle differentiation through the activation of MyoD gene expression in mouse and chicken myoblasts [26, 27] . Recently, RA has also been observed to enhance myoblast survival through induction of Glutathione peroxidase 3 [24] . Collectively, these data strongly suggest an important role of retinoid metabolism in muscle development. Some provitamin A carotenoids are essential precursors for the formation of biologically active retinoids. They could act indirectly on muscle development, through production of retinoids in duodenum and liver, and subsequent delivery to the muscle tissue. The objective of the present study was to test the hypothesis that they could also act directly on the muscle tissue via BCO1. If this was the case, dietary supplementation with provitamin A carotenoids, such as BC, instead of vitamin A, could trigger a local stimulation of retinoid action in skeletal muscle.
First, using avian myoblasts, we show that the BCO1 gene is expressed at both myoblast and myotube stages. Second, the provitamin A carotenoid BC reduces proliferation and increases myogenic cell commitment into differentiation. Then, using a specific inhibitor of the RALDH activity, we demonstrate the implication of the retinoic acid pathway in these processes. This results is confirmed by the observation of increased RARβ expression consecutive to BC treatment. Finally, by using genetic variant and siRNA transfected models, we observed that the response to BC can be reduced by BCO1 downregulation.
Material and methods

Cell culture
Chicken satellite cell-derived myoblasts were obtained from the Pectoralis major muscle of animals genotyped, or not, at the BCO1 gene (AN57A and GN57G haplotypes, denoted as A and G). These two haplotypes were genotyped by high-resolution melting curve analysis as described previously [19] . For comparison between genotypes, myoblasts were prepared from homozygous AA and GG chickens. The "ungenotyped" myoblasts population was obtained by pooling primary cells derived from 14 ungenotyped animals. For all muscles, we used a cell extraction protocol that has been developed in mammals [28] . Muscles were minced and rinsed in PBS. Fragments were enzymatically dissociated with a solution of protease 0.14% (type XIV, Sigma) using a sequential protocol: four successive 10 min cycles of digestion-centrifugation were applied. Primary cells were seeded from 30,000 to 200,000 cells per cm 2 in proliferation medium: DMEM-HamF12 (Sigma) with 10% of foetal calf serum (PAA Laboratories) and 2% of ultroser G (Pall Biosepra). One to 3 days after the seeding, cells were trypsinized and suspended in proliferation medium supplemented with 10% DMSO (Sigma) and frozen at −80°C in a freezing container (Nalgene) before storage in liquid nitrogen. Cells genotyped or not were subcultured up to 9 passages before other experiments by seeding cells at 2500-3000 cells/cm 2 and cell quality was controlled by Pax7 immunolabelling. Successive passages increase the Pax7 cell percentage, the population obtained was called Pax7-enriched population. In each experiment, Pax7-enriched cells were thawed and seeded in cell factory and/or cell plates 40 h before the treatment at a density of 10,000 cells/cm 2 in proliferation medium.
Before the experiments, some primary myoblasts deriving from homozygous AA and GG chickens were characterized by immunocytochemistry at day 2 after seeding in the proliferative stage and following a further 3 days in a differentiation medium (DMEM, 2% horse serum and 2% chicken serum, all products from Sigma) in the differentiated state.
Chemicals
Crystalline all trans β-carotene (Sigma) was solubilized at 1 mg/ml in tetrahydrofuran (THF) with 250 ppm butylated hydroxytoluene (BHT) (Sigma) as a stock solution before storage at −20°C. Indeed, spectrophotometric analyses revealed a much better preservation during storage at −20°C of the BC solution in THF-BHT solvent compared to THF only (not shown). Before use, the concentration of BC was estimated by spectrophotometric analysis using an Infinite M200 plate reader (Tecan Austria GmbH) in water dilutions (2% of the stock solution). The BC molar extinction coefficient is 135,110 l mol −1 cm −1 in THF. We used the spectrophotometric measurement of BC concentration in THF-BHT (2% of the stock solution) to estimate the molar extinction coefficient in water solutions and finally to estimate the BC concentration in the medium. The mean BC concentration calculated by spectrophotometry and applied on cultures was of 2.37 ± 0.15 µM. Less than 0.5% of the stock solution was finally used to treat cells for BC dissolved in THF-BHT for 24-48 h. Diethylbenzaldehyde (DEAB) was dissolved in 95% ethanol and used at 15 µM to treat cells as an aldehyde dehydrogenase inhibitor (less 
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than 0.1% ethanol in the final suspension). DEAB treatment was associated with the BC treatment in parallel to adequate controls (vehicle THF-BHT plus ethanol at less than 0.5%:0.1% v-v).
Flow cytometry
Cell cycle analysis was performed by propidium iodide staining. Cells were trypsinized, centrifuged at 700 g and suspended in cold 70% ethanol and 30% PBS buffer before storage at −20°C for at least 2 h or for weeks. Before staining, cells were incubated for 1 h at 37°C with RNase A (14.4 ng/ml in PBS, Sigma-Aldrich) and then at least 20 min in 10 µg/ml propidium iodide diluted in PBS (Invitrogen). Flow cytometry analysis was performed using a MoFlo® high-speed cell sorter (Beckman Coulter, Fort Collins, CO, USA) equipped with a blue solid-state laser operating at 488 nm and 100 mW. Propidium iodide fluorescence emission was collected with a band-pass filter 630/30 nm. Samples were pre-analysed with the Summit 4.3 software (Beckman Coulter). Cell cycle analysis was finally done using the MultiCycle AV software (Phoenix Flow systems, San Diego, CA, USA).
siRNA transfection
siRNA duplexes against chicken BCO1 were designed and synthesized by Eurogentec (GAGAGACAAUAGCUUGUAU). The scrambled control used was designed using the GenScript web tools (ACAUUGAGUAUAGCGCAUA) and synthesized by Eurogentec. Cells were plated in DMEM HamF12, 10% SVF and 2% ultroser G. The siRNA were transfected 41 h at 35 nM using the Lipofectamine® 
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RNAiMAX reagent (Invitrogen) according to the supplier's recommendations in DMEM HamF12 containing 10% FCS. At 17 h, ultroser G at 2%, BC at 2 µM and vehicle control (THF-BHT) at 0.32% (final concentrations) were added. After a further 24 h, the cells were frozen for RNA extraction or incubated with 10 µM BrdU to evaluate the BrdU incorporation index.
Immunocytochemistry
For quantitative immunocytochemical labelling, cells were cultured in plates and fixed using cold methanol at the end of the experimental procedure. The proportion of Pax7 positive cells (Pax7 cell index) was determined to control the myoblast population quality. The proportion of nuclei incorporating BrdU was used to estimate the proliferation (BrdU incorporation index) and the differentiation index to evaluate the myoblast commitment. Differentiation index was defined as the proportion of nuclei in sarcomeric myosin expressing structures. For BrdU incorporation analysis, cells were pre-incubated 1 h with 10 µM BrdU in proliferation medium and a 20 min 2 N hydrochloric acid DNA denaturation was done after the fixation. After blocking with goat serum 10% (Sigma), cells were incubated with primary antibody supernatants against Pax7 (1/10), BrdU (G3G4, 1/50), and sarcomeric myosin (MF20, 1/50) for 1 h. The Pax7, G3G4 and MF20 antibodies developed respectively by Atsushi Kawakami, Stephen J. Kaufman and Donald A. Fischman were obtained from the Developmental Studies Hybridoma Bank, created by the NICHD of the NIH and maintained at The University of Iowa, Department of Biology, Iowa City, IA 52242. The immunolocalization was then accomplished using a biotinylated goat anti-mouse antibody (anti IgG H+L, Southern Biotech) and with streptavidin-Cy2 (Southern Biotech). All nuclei were labelled using DAPI 0.05 µg/ml (Sigma). 
Imaging
RNA extraction and RT-qPCR analysis
Cells were trypsinized, centrifuged at 700 g, washed in PBS, pelleted and then stored at −80°C before RNA extraction. Total RNA was extracted with the Nucleospin® RNA II kit according to manufacturer's Instructions (Macherey Nagel GmBH & Co, Germany). cDNAs were synthesized using the Superscript II Reverse Transcriptase (Invitrogen, France) and qPCR was performed with the Light Cycler 480 SYBR Green 1 Master reagent (Roche Diagnostics GmBH, Germany) on the Light cycler 480 (Roche). Primers were designed (see Table 1 ) and purchased from Eurogentec. Primers for RARβ (NM_ 205326.1) are sense 5'-GAA ATT CCT GGA TCC ATG CCA CCT CT-3' and antisense 5'-TTG CAC CAT AGG GGA TTG ACT GAC AC-3'. All samples were treated in triplicates. Amplification parameters were as follows: pre-incubation for 5 min at 95°C and 45 amplification cycles of 10 s at 95°C, 20 s at 60°C and 10 s at 72°C. Quantification was done using the Pfaffl procedure [29] and each sample was normalized with an invariant housekeeping gene (eIF3f).
Statistical analysis
Data, presented as mean ± SEM, were analysed with the Statview 5.0 Software (SAS Institute, Inc.). One-way, two-ways and three-ways ANOVA were performed on normally distributed data or log-transformed data with homoscedastic variance. Statistical significance (p < 0.05) was determined using Fisher test. When the data were not normally distributed, a Mann Whitney test was used.
Results and discussion
In chicken, as in mammals [11, 12] the BCO1 gene is expressed at high levels in duodenum and liver where the major part of BC conversion occurs [13] , and at much lower levels in skeletal muscle [19, 30] . In chicken, a polymorphism in the putative promoter of the BCO1 gene is associated with a differential expression of this gene in the Pectoralis major muscle [19] . The corresponding haplotypes denoted AN57A or GN57G, respectively show a high or a low level of expression. This expression is linked to differences in xanthophyll contents and yellow coloration of the meat (GN57G > AN57A). The objective of the present study was to evaluate the physiological signification of BCO1 gene expression in muscle from ungenotyped or genotyped chickens homozygous at the BCO1 locus (respectively denoted as AA or GG for homozygous AN57A or GN57G haplotype). For that purpose, an in vitro model of satellite cell-derived myoblasts isolated from chicken Pectoralis major muscle was used. Proliferation was evaluated by measuring the BrdU incorporation index, while myogenicity and differentiation was evaluated by the proportion of Pax7 expressing cells and calculation of the differentiation index, respectively. Immunostaining with antibodies against BrdU and the sarcomeric myosin at the proliferative (P) and differentiated (D) stages The same profile was observed for slow 2 myosin heavy chain expression. Statistical significance was determined by a three-way ANOVA analysis (G, BC, si) of logtransformed data (n = 6).
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Experimental Cell Research 358 (2017) [140] [141] [142] [143] [144] [145] [146] showed no difference between AA and GG myoblasts (Fig. 1A) . In both AA and GG myoblasts, between P and D stages, the BrdU incorporation index decreased (p < 0.0001), while the differentiation index increased (p < 0.0001) as usually shown in related in vitro models of myogenesis (Fig. 1B) . Regardless of genotype, a proportion of 35-40% of myoblasts was positive for Pax7 indicating the high myogenicity of these populations. The proportion of Pax7 positive cells was reduced in the differentiated stage compared to the proliferative stage (data not shown), as expected from previously published data showing that Pax7 expression decreases when cells enter the differentiation process [31] . Consistently, MyoD mRNA expression decreased (p = 0.02) and MHCs expression increased (p = 0.003) in differentiated compared to proliferative cells (Fig. 1C) . BCO1 expression was detected at both stages and at similar levels in proliferative and differentiated cells (Fig. 1C) . While BCO1 protein expression had previously been reported in human muscle cross-sections [30] and BCO1 mRNA expression in whole chicken muscles [16] , this is the first report of BCO1 expression in skeletal myoblasts derived from satellite cells. Concerning the comparison of the two genotypes, the most striking result concerned BCO1 expression, which was significantly and markedly higher in AA than in GG cells, about 3-fold, as observed previously in chicken Pectoralis major muscle [19] . Under these standard conditions, where substrates of the BCO1 enzyme, such as BC, were absent in the culture media, myoblasts from the AA or GG genotype showed a similar profile of development (Fig. 1) . Following the observation of BCO1 gene expression in cultured myoblasts, we decided to assess the consequences of supplying the provitamin A carotenoid BC [32] to "ungenotyped" chicken myoblasts showing a level of BCO1 expression similar to the AA genotype. Following several passages in vitro, a Pax7-enriched-population was obtained. With the hypothesis that BCO1 activity should lead to production of retinoic acid, the effect of BC on the proliferation of those cells was characterized. The number of BrdU positive nuclei was lower in BC treated compared to control cells ( Fig. 2A) which was further substantiated by a decrease of the BrdU incorporation index (−10%, n = 10, p < 0.01, Fig. 2C ). The cell cycle profile showed a clear increase of G0/G1 cell number (p = 0.025, Fig. 2B, 2D) . Furthermore, the percentages of cells in the S and G2/M phases were reduced by BC addition (n = 6, p = 0.025 and p = 0.045, respectively, Fig. 2D ). Overall, these results suggested that BC reduced myoblast proliferation, as previously observed in human aortic smooth muscle cells [8] or in HeLa Cells [33] .
Besides, the increased proportion of cells in G0/G1 phase of the cell cycle suggested an exit from the cell cycle and an increased commitment of myoblasts into the differentiation process. These results are in accordance with earlier observations following RA treatment of mouse or avian myoblast cell cultures, where proliferation is inhibited and differentiation is enhanced [26, 27, 34] . This increased commitment was confirmed by the increase of the differentiation index after BC treatment (Fig. 4B) . A dose response assay was then performed and the effect of BC was measured 24 h after the treatment. As shown in Fig. 3 , BrdU incorporation linearly decreased with BC concentration (from 0.6 to 2.4 µM, p < 0.0001). Higher concentrations of BC were not tested to limit the concentration of solvent needed (up to 0.5%) and the risk of cell toxicity. In our conditions, the solvent did not seem to induce an unspecific toxicity as nuclei morphology remained normal, without events like nuclear fragmentation or condensation ( Fig. 2A) . This linear effect suggested a high efficiency of BCO1 to cleave BC. As the halfmaximal effective concentration could not be determined in our doseresponse study, we chose to use the maximal dose tested in further experiments.
To evaluate if the effect of BC was exerted through RA production, we treated cells with DEAB, an inhibitor of RALDH activity and RA synthesis [35, 36] . While BC significantly inhibited BrdU incorporation (Fig. 4A) and increased the differentiation index (Fig. 4B ) in the absence of DEAB at 48H, both effects disappeared in the presence of DEAB, which itself did not exert a significant effect on either parameter. These results are in agreement with those obtained in mouse and chicken myoblasts treated with retinoic acid [26, 27] , further demonstrating that the effect of BC in avian myoblasts implied RA production. A similar mechanism has been previously observed in hepatic stellate cells [37] , where BC conversion into RA induced a fat storage phenotype [37] and in hematopoietic stem cells [38] .
In order to evaluate the involvement of the BCO1 enzyme in this pathway, myoblast expressing the BCO1 gene at different levels were compared for their response to BC. Variations of BCO1 activity resulted from the genetic origin of the cells (GG vs. AA), from transfection of siRNA, or both. As expected, both factors exerted a significant effect on the level of BCO1 mRNA, and no interaction was observed (Fig. 5) . Myoblasts from GG chickens showed a significantly lower level of BCO1 expression than myoblasts from AA chickens (−61%, Fig. 5A ), consistent with the difference observed in primary cells (−74% , Fig. 1B) . These last results demonstrated that the differential expression due to the genetic status was maintained after several passages in vitro. In myoblasts of either genotype, transfection of a siRNA targeting BCO1 decreased the expression of BCO1 (−71%). For those different cell preparations, BC treatment induced an increased expression of RARβ, a well-known RA responsive gene [24, 39] , without interaction with cell origin or transfection (Fig. 5B ). This result strengthened our hypothesis that BC could affect RA production in the cells. Indeed, the response of chicken myoblasts to BC was similar to that observed un human myoblasts treated with RA [24] . BrdU incorporation was significantly and markedly inhibited at 24H by BC treatment (p = 0.005), siRNA transfection (p < 0.0001), but surprisingly not altered by genotype (p = 0.65). An interaction between genotype and BC treatment was suggested (p = 0.07, Fig. 6A ). BC decreased BrdU incorporation in AA (20%, p = 0.01), but not in GG (p = 0.52), which is consistent with the hypothesis that decreased BCO1 gene expression blunted the effect of BC in GG myoblasts. By contrast, the inhibitory effect of BC on BrdU incorporation index was not fully inhibited by siRNA transfection (Fig. 6B) .
Given that BCO2 provides an alternative pathway for BC cleavage, we decided to measure its expression in both conditions. While BCO2 mRNA levels were not affected by genotype, they were increased in myoblasts treated by siRNA targeting BCO1 (p = 0.003) (Fig. 7A ). This suggests that decreased BCO1 expression following siRNA treatment could be compensated by an increase of BCO2 expression, as previously observed in BCO1 KO mice [14] . Overexpression of BCO2, which inhibits prostate cancer cell proliferation independently of its enzymatic activity [40] , could explain the decreased BrdU incorporation index (Fig. 6B ) and increased MHCs2 expression (Fig. 7B ) in BCO1 siRNA transfected myoblasts in the absence or presence of BC. The residual response to BC could imply the production of β-apocarotenoids, products of BCO2 enzyme activity, which inhibit breast tumor cell proliferation, independently of the RA pathway [41, 42] . Alternatively, a residual activity of the BCO1 enzyme cannot be excluded as RARβ expression was also induced by BC treatment in those cells. However, such a compensatory mechanism does not seem to operate following genetic variation at the BCO1 locus. Our results are consistent with those previously obtained in vivo where the reduced BCO1 expression observed in GG compared to AA chickens is not associated with altered BCO2 expression, despite consequences on lutein and zeaxanthin concentrations in Pectoralis major muscle [20, 43] .
Overall our results indicate that in chicken myoblasts, BC is converted through the BCO1 pathway into RA, which subsequently inhibits their proliferation and enhances their differentiation. In case of BCO1 deficiency following siRNA treatment, the BCO2 gene is overexpressed, leading to a decreased proliferation independent of BC and possibly contributing to a residual response to BC. However, in the genetic variant that has lost the compensatory regulation mediated by BCO2, the decrease in BCO1 expression is associated to a lack of response to BC.
Conclusion
Our study shows that BC can directly act on myogenic cells and that its effects are mediated by a local activation of the retinoic acid pathway. BC affects the transition from proliferation to differentiation of Pax7-enriched chicken myoblasts by inhibiting their proliferation and increasing their commitment into the differentiation process. Our study also demonstrated that the modulation of myoblasts activity by BC is mediated by the intracellular production of RA, which relies predominantly on the activity of the BCO1 gene. From an applied perspective, we suggest that dietary BC could be efficient to regulate myogenesis and satellite cell activity in vivo.
